Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Clasificación temprana de cáncer de próstata agresivo

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20180921002
Publicado:
19/10/2018
Caducidad:
20/10/2019
Resumen:
Una universidad alemana ha descubierto una proteína (vimentina 3) que se emplea como marcador para determinar la tendencia de los tumores de próstata a desarrollar metástasis. Los resultados han mostrado una alta expresión de vimentina 3 en células de cáncer de próstata metastásico y baja expresión en cáncer no metastásico, desmostrando el potencial de la vimentina 3 para la estratificación de riesgo de carcinoma de próstata localizado y facilitar así la planificación de una terapia personalizada. La universidad busca compañías del sector de diagnóstico especializadas en detección de tejidos y en técnicas de detección de líquidos (sangre, suero) con el fin de establecer acuerdos de licencia y cooperación en materia de investigación.

Details

Tittle:
Early classification of aggressive prostate cancers
Summary:
A German university has discovered a protein that can be used as a marker to determine the tendency of prostate tumors to metastasize. The university offers a license and research cooperation agreement.
Description:
Prostate cancer is the second most common cancer in males. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of the cancers diagnosed in males. The selection of the therapeutic strategy depends on the risk classification. There is a strong medical need to precisely identify those patients whose disease allows monitoring without therapeutic intervention, in order to avoid overtreatment, which comes along with high medical costs and loss of life quality.

The diagnosis, classification and therapy of prostate cancer are based on the prostate-specific antigen (PSA) test value, the Gleason score from histology obtained by prostate biopsies and an imaging diagnosis from computer tomography (CT) and bone scintigraphy. The variability of prostate cancer ranges from low-risk tumors without progression over many years to high-risk tumors with rapid local progression and high metastasis potential. There is a correlation with the risk for metastasis and the Gleason score, however there is an ongoing search for new biomarkers that directly correlate with the risk for metastasis.

A German university discovered vimentin 3 (Vim3) as biomarker, which correlates with the risk of progression of prostate cancer. Results show high expression of Vim3 in cells of metastatic prostate and low expression in non-metastatic cancer, thus demonstrating the potential of Vim3 for risk stratification of localized prostate carcioma to enable personalized therapy planning.

Vim3 is a truncated and biologically active variant of vimentin. healthy cells express the vimentin full-length variant (Vim-fl) and are characterized by a functional cytoskeleton. If Vim-fl is no longer expressed in the cells, Vim3 is predominantly detectable. In this case the intracellular structure of the cell is disordered due to the loss of the normal cytoskeletal architecture with the consequence that cells become deformable and consequently mobile.

The university offers a license agreement to companies in the diagnostics industry, specialized in tissue detection and those specialized in detection techniques for liquids (blood, serum e.g.). The results generated in the German university still need to be validated in the form of larger studies and need a further development for clinical use. Therefore a research cooperation agreement can be included in the agreement.
Advantages and Innovations:
This new marker improves the decision support of a physician regarding a therapy plan. The special feature compared to the currently used markers is that the tendency of the tumor to metastasize can be determined.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European patent has been applied for.

Partner sought

Type and Role of Partner Sought:
The university offers a license agreement to companies in the diagnostics industry, specialized in tissue detection and those specialized in detection techniques for liquids (blood, serum e.g.). The results generated in the German university still need to be validated in the form of larger studies. Therefore a research cooperation agreement can be combined with it.

If the invention is to be used as a diagnostic agent, the results generated at the university must be validated in larger studies, which will be the task of the company sought. This is where the scientists are involved (sample material, previous test procedure). It may also be necessary to develop the potential diagnostic agent into a mature product (e.g. a kit with corresponding reagents or test strips). This will probably also be done by the sought-after partner and will also involve the university.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis